Barclays Maintains Equal-Weight on Tandem Diabetes Care, Raises Price Target to $20
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Barclays analyst Christopher Pasquale maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Equal-Weight and raises the price target from $18 to $20.
Barclays analyst Christopher Pasquale maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Equal-Weight and raises the price target from $18 to $20.